CTOs on the Move

Cannalysis Labs

www.cannalysislabs.com

 
Cannalysis was founded in 2015, in Costa Mesa CA. Initially, Cannalysis exclusively served Southern California with a limited amount of analyses available. As the operational and testing requirements expanded, Cannalysis moved its headquarters to a 12,000 sqft state-of-the-art facility in Santa Ana, CA.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Cannalysis Labs raised $22.6M on 09/19/2019

Similar Companies

Axiom Real-time Metrics

Axiom Real-time Metrics is a Oakville, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SiChuan Sanherb Biotech

SiChuan Sanherb Biotech is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioAge Labs

BIOAGE has a diverse team of computational biologists and medical scientists with expertise in aging and translational research. We share the vision that a synergy of machine learning approaches, high throughput human omics data, and new experimental approaches will make it possible to discover therapies that address unmet medical needs in an aging population.

Turnstone Biologics

Turnstone Biologics, a privately held clinical stage biotech company, is developing breakthrough cancer immunotherapies by advancing two leading and complementary platforms that drive innate and adaptive tumor immunity, to provide benefit to the millions of cancer patients underserved by current treatment options. Turnstone`s proprietary vaccinia virus platform is engineered to drive coordinated immune activation, potent viral activity, and local expression of encoded therapeutics. The innovative TIL cell therapy platform leverages clinically validated treatment protocols and has been specifically designed to extend beyond the use of bulk TILs to enrich for the most relevant T-cells for tumor eradication, preserving broad antigen diversity and minimizing treatment times to patients. The Company has an ongoing Phase 1/2a trial in solid tumors (RAPTOR) for its leading oncolytic virus candidate, RIVAL-01, and is expecting to file an IND for the lead TIL therapy candidate, TIDAL-01, in 2021.